Physician profile
Emma Davis
NPI 1598437485
$2,727.76
in general payments reported to CMS, 2019-2025
25 companies · $1,226 in 2025
The $1,226 reported for 2025 was more than what 86% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $66.32 · 2022: $335 · 2023: $450 · 2024: $650 · 2025: $1,226.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,151 · Education: $175.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,151.36 |
| Education | $174.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $403.98 | 2024-2025 | Tremfya |
| Abbvie INC. | $395.43 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $386.83 | 2024-2025 | Dupixent, Libtayo |
| Ucb, INC. | $278.22 | 2024-2025 | Bimzelx |
| Sun Pharmaceutical Industries INC. | $229.92 | 2024-2025 | |
| Pfizer INC. | $172.11 | 2022-2025 | |
| Myriad Women'S Health, INC. | $142.14 | 2023 | Bracanalysis Cdx |
| Astellas Pharma US INC | $137.46 | 2022-2023 | Myrbetriq |
| Millicent US INC | $102.53 | 2022-2023 | Intrarosa, Femring |
| Incyte Corporation | $72.00 | 2025 | Opzelura |
| Novartis Pharmaceuticals Corporation | $56.97 | 2024-2025 | |
| Leo Pharma INC. | $56.67 | 2025 | Adbry, Anzupgo |
| Mayne Pharma Commercial LLC | $40.37 | 2022-2023 | |
| Genzyme Corporation | $39.18 | 2025 | |
| Amgen INC. | $28.76 | 2025 | Otezla |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $25.49 | 2024 | Sotyktu |
| Mycovia Pharmaceuticals, INC. | $24.63 | 2022 | |
| Exeltis, USA INC. | $23.94 | 2021 | |
| Gynesonics, INC. | $22.07 | 2023 | Sonata Sonography-Guided Transcervical Fibroid Ablation System |
| Baxter Healthcare | $20.17 | 2023 | Adept |
| Botanix Sb INC | $18.72 | 2025 | Sofdra |
| Sumitomo Pharma America, INC. | $18.33 | 2023 | Myfembree |
| Lilly USA, LLC | $17.04 | 2024 | Taltz |
| Axonics, INC. | $13.24 | 2023 | Axonics |
| Organon LLC | $1.56 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emma Davis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.